ENLV has $16 per share worth of RAIN tokens in the balance sheet and SP is at $0.85

Enlivex Ltd. (ENLV) is Nasdaq listed biotech that has quite promising drug in phase 2. But contrary to the usual biotech firm this is actually not the most important thing about the company at this junction. Reason is there's quite unique opportunity available due to their crypto treasury strategy where some time ago they invested a lot of money to crypto token called RAIN. Since then the Rain protocol has gained a lot of interest and based on today's market price of the token the company has accumulated over $16 per share worth of tokens (actual tokens and options to buy tokens at deep discount) in the balance sheet. The share price is currently quite surprisingly at $0.85 which means their market cap is only around 5% of their balance sheet value.

The price of token can and probably will fluctuate a lot based on how the underlying protocol gains or won't gain further popularity. But this is the valuation cap as of today and since the token at least currently has quite large daily trading volume of $60 million it's not one of those very small cryptos that nobody has heard of meaning there's most likely some stickiness to the token price compared to many smaller ones. Furthermore underlying rain protocol is fast becoming one of the biggest prediction market protocols and is actually already the biggest fully decentralized one (per TVL). As some of you may know prediction market is currently one of the most interesting areas of general crypto industry so the future does also seem very exciting for the underlying rain token which could easily mean even bigger balance sheet for the company.